1.基本情况
饶勇 男 中国共产党党员，博士 研究员 硕士生导师
电话：**；电子邮箱：raoyong0805@126.com
2.教育背景
2006.9-2010.6 湖北师范大学 生命科学学院 理学学士
2010.9-2013.6 广东医科大学 基础医学院 医学硕士
2013.9-2016.6中山大学 药学院 理学博士
2016.7-2021.7 中山大学 药学院 副研究员
2021.8起 海南大学药学院 研究员
3.科研情况
主持项目4项，包括国家自然科学基金青年项目，广东省自然科学基金面上项目等。以项目第一参与人参与科研项目总经费约900万，包括国家自然科学基金重点项目、面上项目；广州市民生科技重大专项等。共发表SCI论文13篇，其中一作/通讯（含）论文10篇，中科院一区论文9篇；申请/授权专利6项，PCT专利3项。
4.研究领域
慢性脂肪性肝病与神经退行性疾病分子药理学与创新药物研究；
线粒体代谢调控分子药理学研究；
5.社会兼职
担任J Med Chem, Eur J Med Chem, Brit J Pharmacol等药化药理学杂志审稿人
6.代表性项目
1）国家自然科学基金青年基金，抗非酒精性脂肪性肝炎（NASH）新型先导化合物发现及作用机制研究，主持
2）广东省自然科学基金面上项目，新型HSP90抑制剂的设计合成及其调控能量代谢抗非酒精性脂肪性肝炎活性与新机制研究，主持
3）中山大学青年培育项目，苦参碱类新型HSP90抑制剂的设计合成及其抗非酒精性脂肪性肝炎（NASH）应用研究，主持
4. 广西师范大学省部共建药用资源化学与药物分子工程国家重点实验室开放课题：新型HSP90抑制剂苦参碱抗非酒精性脂肪性肝炎新机制研究，主持
5）国家自然科学基金重点项目，能量代谢调控新靶点、新机制发现与创新药物研究，第一参与人
7. 代表性成果
1) Yong Rao^{1, *}, Zhiqi Kuang, ChaN Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, Zhishu Huang^*, Yongjun Lu^*. Gut Akkermansia muciniphila ameliorates metabolic dysfunction associated fatty liver disease by regulating the metabolism of L-aspartate via gut liver axis. Gut Microbes. 2021, 13, 1-19. (IF10.245)
2) Yong Rao^*, Yu-Ting Lu, Chan Li, Qin‐Qin Song, Yao‐Hao Xu, Zhao Xu, Yu‐Tao Hu, Hong Yu, Lin Gao, Lian‐Quan Gu, Ji‐Ming Ye^*, Zhi‐Shu Huang^*. Bouchardatine analogue alleviates non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol., 2019, 176, 2877-2893. (IF8.739)
3）Yong Rao, Hong Yu, Lin Gao, Yu-Ting Lu, Zhao Xu, Hong Liu, Lian-Quan Gu, Ji-Ming Ye^*, Zhi-Shu Huang^*. Natural alkaloid bouchardatine ameliorates metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1/liver kinase B-1/AMPK axis. Br J Pharmacol., 2017, 174, 2457-2470. (IF8.739)
4) Qin-Qin Song¹, Yong Rao¹, Gui-Hua Tang¹, Zhang-Hua Sun, Jun-Sheng Zhang, Zhi-Shu Huang^*, Sheng Yin^*. Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes. J Med Chem., 2019, 2060-2075. (IF7.446)
5) Yong Rao¹, Hong Liu¹, Lin Gao, Hong Yu, Tian-Miao Ou, Jia-Heng Tan, Shi-Liang Huang, et al. Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives as Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment. J Med Chem., 2015, 58, 9395-9413. (IF7.446)
6) Yong Rao^1，*, Zhao Xu¹, Yu-Tao Hu, Chan Li, Yao-Hao Xu, Qin-Qin Song, et al. Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders. Eur J Med Chem., 2020, 192, 112172. (IF6.514)
7) Lin Gao, Zhao Xu, Yong Rao*, Yu-Ting Lu, Yu-Tao Hu, Hong Yu, Yao-Hao Xu, et al. Design, synthesis and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Eur J Med Chem., 2018, 147, 90-101. (IF6.514)
8) Yong Rao, Hong Liu, Lin Gao, Hong Yu, Jia-Heng Tan, Tian-Miao Ou, Shi-Liang Huang, Lian-Quan Gu, Ji-Ming Ye, Zhi-Shu Huang. Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Bioorg Med Chem., 2015, 23, 4719-4727. (IF3.641)
9) Yao-Hao Xu, Qin-Qin Song, Chan Li, Yu-Tao Hu, Bing-Bing Song, Ji-Ming Ye, Yong Rao?, Zhi-Shu Huang. Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis. Eur J Pharmacol., 2019, 854, 328-337. (IF4.432)
10) Yao-Hao Xu, Wei Li, Yong Rao*, Zhi-Shu Huang, Sheng Yin *. Pyridocarbazole alkaloids from Ochrosia borbonica: lipid-lowering agents inhibit the cell proliferation and adipogenesis of 3T3-L1 adipocyte via intercalating into supercoiled DNA. Chinese Journal of Natural Medicines. 2019, 17, 663-671. (IF3.0)
11) Chen-Xi Wang, Zi-Lin Zhang, Qi-Kun Yin, Jia-Li Tu, Jia-En Wang, Yao-Hao Xu, Yong Rao, et al. Design, Synthesis, and Evaluation of NewQuinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors. J Med Chem., 2020, 63, 9752-9772. (IF7.446)
12) Chao-Yun Cai, Li Rao, Yong Rao, Jin-Xuan Guo, Zhi-Zun Xiao, Jing-Yu Cao, Zhi-Shu Huang, Bo Wang. Analogues of xanthonesddChalcones and bis-chalcones as aglucosidase inhibitors and anti-diabetes candidates. Eur J Med Chem., 2018, 147, 90-101. (IF6.514)
13) Wei Li, Ya-Qi Tang, Shi-Xin Chen, Gui-Hua Tang, Li-She Gan, Chan Li, Yong Rao, Zhi-Shu Huang, and Sheng Yin. Euphorhelipanes A and B, Triglyceride-Lowering Euphorbia Diterpenoids with a Bicyclo[4.3.0]nonane Core from Euphorbia helioscopia. J Nat Prod., 2019, 82, 412-416. (IF4.05)
8.荣誉奖励
2021年8月以海南省高层次人才引进进入海南大学药学院
9. 其他
欢迎对科研满怀热情的药学、生物学、基础医学相关人才加入。